Fig. 1
From: TET1 mutations as a predictive biomarker for immune checkpoint inhibitors in colon adenocarcinoma
Landscape of TET1 mutations in COAD. A The frequencies of mutant genes and clinical features between TET1 wild-type and mutated patients in the ICI-treated cohort (MSKCC-COAD). B The frequencies of mutant genes and clinical features between TET1 wild-type and mutated patients in the non-ICI-treated cohort (TCGA-COAD). C Comparison on the mutation sites of TET1 gene in MSKCC- and TCGA-COAD cohorts